A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Trial Details

NCT ID
NCT06116786
Phase
PHASE1
Sponsor
Johnson & Johnson Enterprise Innovation Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • JNJ-86974680
  • Cetrelimab
  • Radiation Therapy
Locations (sample)
  • Newnan, Georgia, United States|33.38067,-84.79966
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Buffalo, New York, United States|42.88645,-78.87837
  • New York, New York, United States|40.71427,-74.00597
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
  • Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\],…
  • Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1…
  • Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →